Union Bancaire Privee UBP SA Invests $282,000 in BioNTech SE (NASDAQ:BNTX)

Union Bancaire Privee UBP SA bought a new stake in shares of BioNTech SE (NASDAQ:BNTX) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 2,500 shares of the company’s stock, valued at approximately $282,000.

A number of other hedge funds have also recently made changes to their positions in BNTX. FMR LLC boosted its position in BioNTech by 797.8% in the 3rd quarter. FMR LLC now owns 6,299,929 shares of the company’s stock valued at $748,243,000 after buying an additional 5,598,190 shares during the period. Fred Alger Management LLC purchased a new position in shares of BioNTech during the third quarter worth approximately $59,485,000. Braidwell LP purchased a new stake in shares of BioNTech in the third quarter valued at approximately $29,425,000. New York State Common Retirement Fund grew its stake in BioNTech by 457.9% in the third quarter. New York State Common Retirement Fund now owns 218,067 shares of the company’s stock worth $25,900,000 after purchasing an additional 178,981 shares in the last quarter. Finally, abrdn plc increased its holdings in BioNTech by 334.4% during the 3rd quarter. abrdn plc now owns 225,992 shares of the company’s stock worth $26,841,000 after purchasing an additional 173,969 shares during the period. 15.52% of the stock is currently owned by institutional investors.

BioNTech Stock Down 2.5 %

Shares of NASDAQ BNTX opened at $116.98 on Tuesday. The company has a market capitalization of $28.04 billion, a P/E ratio of -55.70 and a beta of 0.17. BioNTech SE has a 1 year low of $76.53 and a 1 year high of $131.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The company has a 50 day simple moving average of $117.32 and a 200-day simple moving average of $111.29.

Wall Street Analysts Forecast Growth

BNTX has been the subject of several research reports. Wells Fargo & Company began coverage on shares of BioNTech in a research report on Wednesday, December 11th. They issued an “overweight” rating and a $170.00 price target for the company. JPMorgan Chase & Co. lowered their target price on BioNTech from $124.00 to $122.00 and set a “neutral” rating for the company in a report on Tuesday, November 26th. TD Cowen cut their price target on BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a report on Tuesday, November 5th. Berenberg Bank started coverage on BioNTech in a research note on Tuesday, November 19th. They set a “buy” rating and a $130.00 price objective for the company. Finally, Canaccord Genuity Group lifted their target price on BioNTech from $171.00 to $171.44 and gave the company a “buy” rating in a research note on Wednesday, November 27th. Three equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, BioNTech currently has an average rating of “Moderate Buy” and an average price target of $142.72.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.